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Abstract
In several tumors the transketolase activity, controlled inter alia by enzymes of the pentose
phosphate pathway which is an alternative, energy generating reaction-cascade to glycolysis, has
been correlated with proliferation. The increase of thiamine-dependant transketolase enzyme
reactions is induced especially through upregulated transketolase-like enzyme 1 (TKTL1)-activity;
that shows TKTL1 to be a causative enzyme for tumors enhanced, anaerobic glucose degradation.
We investigated TKTL1-expression in 88 human, formalin-fixed non-small cell lung cancer tissues
and 24 carcinomas of the breast by immunohistochemical stainings applying a 0 to 3 staining-score
system (3 = strongest expression). For means of validation we additionally stained 40 NSCLC fixed
and paraffin-embedded utilizing the HOPE-technique; showing comparable results to the formalin-
fixed, paraffin-embedded specimens (not shown). Potential correlations with age, sex, TNM-
classification parameters and tumor grading as well as tumor transcription factor 1 (TTF1) and
surfactant protein A (SPA) expression were investigated. 40.9% of the analyzed lung tumors
expressed TKTL1 weakly (Score 1), 38.6% moderately (score 2) and 17.1% strongly (score 3). 3
tumors were diagnosed TKTL1-negative (3.4%; score 0). All Breast cancer specimen stainings were
positive and scored 1: 32%; scored 2: 36%; scored 3: 32%. Alveolar macrophages and Alveolar
Epithelial Cells Type II were also found to be TKTL1-positive.
None of the listed clinical parameters could be found to show a significant correlation to TKTL1
signal appearance.
Although we describe the expression of TKTL1 in lung cancers, we need to state that up till now
there is no scientific indication for any treatment regimens based upon these findings.
Findings
The ability of tumors to degrade glucose, even in the pres-
ence of oxygen, through the anaerobic transketolase-
dependant pentose phosphate pathway has recently
shown TKTL1 to particularly influence total transketolase
activity and cell proliferation [1]. TKTL1 mRNA silencing
(via small interfering anti-TKTL1-mRNA constructs) leads
to inhibition of cell proliferation in colorectal cancer; pro-
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overexpression was found in breast cancer cells where
89% expressed TKTL1 and 45% showed strong expression
[2,3]. Gastric tumors and granulosa cell tumors of the
ovary were also found to express high amounts of TKTL1
(36.9%; 81%) [4,5]. Further, with renal cancer another
carcinoma displayed intensively elevated transketolase
activity due to TKTL1-upregulation [6]. Proliferation-
influencing activities of TKTL1 might play a role in a vari-
ety of cancers. Hence we investigated a capacious collec-
tive of 88 formalin-fixed non-small cell lung cancer
(NSCLC)-tissues (39 adenocarcinomas; 49 squamous cell
carcinomas) by immunohistochemistry to describe TKTL1
protein expression in human lung carcinomas. A collec-
tive of 24 breast cancer specimens was also included in the
study (21 invasive-ductal; 1 tubular; 1 lobular; 1 muci-
nous carcinoma). Further, we challenged a potential cor-
relation of TKTL1 to age, sex, TNM-classification and
grading as well as TTF1 and SPA expression.
After lobectomy or pneumonectomy tumor tissues were
immediately fixed with formalin and processed in the fol-
lowing over-night-procedure: formalin 1 h 30 min; fol-
lowing an alcohol series (70% 1 h 30 min; 80% 1 h; 96%
1 h for 2 times; 100% 1 h for 3 times; Histoclear for 1 h 2
times; subsequently paraplast is brought into the tissue at
60°C for 1 h 30 min; then another 2 h). Each step was fol-
lowed by a 30 min. drop-off delay before the next step was
started. After resection breast cancer specimens were proc-
essed in the same manner. Additionally we investigated
40 HOPE (Hepes Glutamic Acid Buffer Mediated Organic
Solvent Protection Effect)-fixed NSCLC-tissue probes to
validate the formalin fixation. After embedding in paraf-
fin the blocks were shelved for 0–6 years within a tissue
archive. For increased inter specimen comparability and
even staining quality we utilized Tissue Microarrays
(TMAs). These TMAs were produced from donor tissue
blocks using an MTA1 (Manual Tissue Arrayer 1) device
(Alphametrix, Germany), cut and mounted on micro-
scope slides (Super Frost Plus, Langenbrink, Germany).
For homogeneous high-throughput staining conditions
the tissues were stained automatically (Autostainer 480,
Medac, Germany).
The TMAs were deparaffinized and rehydrated by the fol-
lowing series at room temperature: 10 min. xylol incuba-
tion; 2 min. absolute alcohol (2 times); 2 min. 96%
alcohol (2 times); 2 min. 90% alcohol; 2 min. 80% alco-
hol; 2 min. 70% alcohol; 2 min. aqua dest. (2 times). For
antigen retrieval 30 min. citrate buffer cooking in was cho-
sen. The primary antibody (anti-TKTL1; clone: JFC12T10;
Zytomed Systems, Berlin) was incubated for 30 min. in a
1:100 dilution. We used an enzyme-polymersystem
(ZytochemPlus HRP Polymer Kit, Zytomed Systems) for
sensitive detection with permanent AEC (Zytomed Sys-
tems) as chromogen. Tissue arrays were counterstained by
incubation in Mayer's haemalum for 5 minutes. Negative-
controls were included in each staining series under omis-
sion of primary antibody.
The immunohistochemical stainings displayed elevated
expression of TKTL1 in human lung cancer: 40.9%
expressed TKTL1 weakly (score 1), 38.6% moderately
(score 2), 17.1% strongly (score 3), and 3.4% of the
tumors were TKTL1-negative (score 0; Figure 1). Breast
cancer specimen stainings were scored 0: none; scored 1:
32%; scored 2: 36%; scored 3: 32% (Figure 2). In general,
adenocarcinomas were more often strongly positive
(score 3) than the squamous cell carcinomas (22.1% for
adenocarcinomas and 12.2% for squamous cell carcino-
mas). Staining of the HOPE-fixed specimens showed
comparable results; these results verify findings in the five
cases of adenocarcinomas of the lung described by Lang-
bein et al. [7].
Signals were recognized in the cytoplasm and occasionally
in nuclei of tumor cells. There was a conspicuous amount
of signal-containing alveolar macrophages and alveolar
epithelial cells type II (AEC II cells), observed in the close
neighborhood of the NSCLC (Figures 3D and 3E) as well
as in completely healthy parts of lung tissue (not shown).
Examples of stained tumor types, alveolar macrophages
and AEC II cells are shown in figure 3A–E. No staining was
found in negative controls. Comparison of TKTL1-expres-
sion to several clinical parameters revealed that there is no
significant correlation between TKTL1-appearance and
age, sex, TNM-classification parameters or tumor grading.
Further no correlation could be defined concerning SPA
and TTF1 expression.
A high variability of TKTL1-expression has been described
in several tumor types. There is proven evidence that
TKTL1-associated or -inducing, abnormal glucose degra-
dation is increased in tumors [3-10]. But TKTL1 is also a
key enzyme in the healthy organism whose activation-sta-
tus influences the balance of anaerobic glucose- or oxy-
gen-focussed bioenergy-obtainment. Natural appearance
is proven through positive detected macrophages and
AEC II cells (Figures 3D and 3E) as well as signals in
healthy lung tissues. Therefore tests on cancer cells or can-
cer tissues alone are not capable to gain insights into the
complex situation in patients subjected to diets or other
treatments. We have shown that a large portion of NSCLC
overexpresses TKTL1; moreover there was a significant
expression in non malignant cells of the lungs. Although
it is tempting to speculate of a potential therapeutic bene-
fit by modulation of TKTL1-activity in the future, further
studies are necessary to investigate the real amount of
effects during TKTL1-targeted diets or therapies within the
human organism.Page 2 of 5
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Allocation of the stained lung cancer specimens to the four different staining scoresFigure 1
Allocation of the stained lung cancer specimens to the four different staining scores. 
Allocation of the stained breast cancer specimens to the four staining scoresFigure 2
Allocation of the stained breast cancer specimens to the four staining scores. 
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